Detalhe da pesquisa
1.
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Breast Cancer Res
; 22(1): 56, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32466779
2.
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
Breast Cancer Res
; 20(1): 40, 2018 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769099
3.
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Oncotarget
; 7(46): 74448-74459, 2016 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27801670
4.
ESR1 mutations in breast cancer.
Aging (Albany NY)
; 9(1): 3-4, 2017 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28130553